MedTrace Logo

The Safety and The Efficacy Evaluation of ET-STEM in Patients With Frontotemporal Dementia

NCT05315661 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-02-21

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the safety and the tolerability of 3 repeated doses of ET-STEM (Mesenchymal stem cells preconditioned with ethionamide) in patients with FTD.

Conditions

  • Frontotemporal Dementia

Interventions

DRUG

ET-STEM

mesenchymal stem cells preconditioned with ethionamide

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • HeeJin Kim · Samsung Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-06
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05315661 on ClinicalTrials.gov